Effect of ADCC Shift in Lots of Trastuzumab Could Change Its Biosimilarity to SB3

In developing a biosimilar to trastuzumab, researchers discovered a downward shift in ADCC in lots of the reference drug suggesting the 2 drugs may not be completely identical.